Breaking News

SGS Adds Stability Testing Services in UK

March 11, 2013

Expands analytical testing for biologics

SGS Life Science Services is developing integrated formulation and stability testing services in the UK, expanding its current capability for characterization-based analytical testing for biologics. The new services will be offered from a dedicated suite in its M-Scan facility in Wokingham, UK and is scheduled to be fully operational by 4Q13.
The 1,100 sq.-ft. suite will include a temperature and access controlled room for the stability units and a large separate instrumentation and wet lab. These new services extend SGS’s formulation and stability services currently provided in Lincolnshire, IL, and stability testing services from its Center of Excellence in Berlin, Germany.
“Customers require preparation and testing of their samples at one site. Sample shipment involved in multisite testing is not ideal because of the potential effects that shipping may have on sample integrity,” said Andrew Reason, group manager, SGS M-Scan Europe. “These studies are also an iterative process whereby data is fed back to the formulation scientists prior to generation of further samples for testing.”
Anne Hays, executive vice president, SGS Life Science Services, said, “There is an increasing trend for biologics manufacturers to outsource testing of their products and SGS strives to provide new services in response to the market’s needs in a timely manner.”
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Biopharmaceutical Contract Manufacturing Capacity Expansions

    Biopharmaceutical Contract Manufacturing Capacity Expansions

    William Downey , HighTech Business Decisions||June 2, 2015
    Biopharma contract manufacturing market continues to expand, expected to grow 8% over the next five years